Digital health products are pitched in three different ways to three different buyers, yet most companies never land on the single claim that truly stands up to scrutiny. We create positioning that can withstand a clinical review, a payer contract negotiation, and a sales call in the same week – rooted in what the product actually does, not what the deck claims it does.
The Problem
Your positioning was created for the previous funding round, not today’s buyer
Most digital health positioning gets locked in during a seed or Series A pitch, built to impress investors rather than convince a health system CMO or a benefits director. That language survives untouched through two more rounds and a dozen sales cycles because nobody owns the job of revisiting it. Meanwhile the product has evolved, the competitive set has changed, and the buyer reading your homepage is not the person the original pitch was written for. The mismatch shows up as long sales cycles and confused prospects who ask what you actually do.
Clinical and marketing claims are developed by different people who never compare notes
Clinical and regulatory teams write conservative, evidence-bound language to avoid overstating efficacy, while marketing writes aspirational copy to compete for attention. When these two voices never reconcile, the website says one thing, the sales deck says another, and the clinical validation packet says a third. A procurement team or medical director who cross-references all three loses trust in the company, not just the claim. Positioning has to be one story that both teams can defend in the same room.
You are positioned against the wrong competitor for the buyer you are speaking to
A payer evaluates you against other cost-containment vendors, a health system evaluates you against point solutions already bolted into the EHR, and a consumer evaluates you against whatever app they saw an ad for last week. Generic positioning that ignores which buyer is in the room forces every seller to improvise the comparison from scratch. Improvised positioning is inconsistent positioning, and inconsistent positioning reads as an unclear product to a buyer already skeptical of health tech claims.
"Better outcomes" and "improved engagement" do not define a category, and every competitor makes the same claims
Digital health marketing is saturated with interchangeable outcome language – better outcomes, higher engagement, lower cost of care – that could describe almost any product in the space. When your positioning uses the same words as five direct competitors, the buyer defaults to price or brand recognition to break the tie, and neither favors an earlier-stage company. Differentiation requires naming the specific mechanism by which your product produces a result, not just claiming the result exists.
How We Can Help
We begin by auditing what the product actually does against what every current asset says it does. That involves reviewing the clinical validation data, the real workflow a user follows, the integration footprint, and an honest inventory of what the product cannot do yet. Most positioning issues stem from this divide between claimed and actual capability, and closing that gap is the prerequisite for everything that follows.
Next, we map the buyer landscape around your specific go-to-market motion. A product sold simultaneously to health systems, payers, and direct-to-consumer channels requires three distinct but coherent framings – not one diluted message intended to work everywhere.
We then develop the positioning architecture: one core claim the entire company can support, paired with channel-specific proof points and flexible language that never becomes contradictory. This covers the category frame (where you sit relative to competitors), the differentiated mechanism (why your approach delivers the result, rather than simply stating that it does), and an objection map for every buyer type.
Execution involves rewriting the assets still carrying the old positioning – website, sales deck, one-pagers, and category-relevant collateral – and briefing the teams that must communicate it aloud, whether sales, customer success, or a clinical advisory board.
To measure progress, we begin with qualitative signals – are prospects accurately repeating the positioning in discovery calls, and are sales cycles getting shorter at the point where positioning is tested – before assessing downstream metrics such as win rate against named competitors.
What distinguishes this from a branding exercise is that we create positioning designed to withstand a skeptical buyer, not win a pitch competition.
What we deliver
- Positioning audit – gap analysis between claimed capability, clinical evidence, and actual product function
- Buyer-specific framing for each channel in play (health system, payer, employer, consumer) built from one core architecture
- Category and competitive frame – the specific shelf you sit on and the mechanism that differentiates you from named competitors
- Rewritten core assets – website messaging, sales deck, one-pagers – aligned to the new positioning
- Team briefing and objection map so sales, customer success, and clinical stakeholders can defend the claim consistently
The digital health companies that succeed are not necessarily those with the strongest outcome data—they are the ones whose clinical, sales, and marketing teams give the same answer when a buyer asks what the product does.
Our Methodology
We conduct positioning engagements as a 90-day sprint. The first 30 days focus on the audit: we collect existing assets, interview clinical, product, and sales stakeholders separately to uncover where their product descriptions differ, and examine win-loss notes or lost-deal feedback when available. This stage typically exposes more internal disagreement than the team anticipated, which is the real indication that the positioning requires work.
Days 30 to 60 cover architecture and drafting. We create the core claim, channel-specific framings, and competitive frame, then test the wording against genuine objections drawn from sales calls and clinical review discussions rather than invented scenarios. Days 60 to 90 shift to asset rewrites and team rollout – refreshing the website and sales materials, briefing the teams responsible for using the language, and establishing qualitative tracking to determine whether the new positioning is taking hold in the field.
Unlike a branding agency, we treat clinical accuracy as a requirement rather than an afterthought – every claim in the final positioning must be defensible to a medical director, not merely convincing to a marketing audience. We also do not deliver a static document and walk away; we remain involved through rollout because positioning that is not repeated correctly in the field was never truly adopted.
Our Working Process
The first 30 days center on discovery and audit. We independently interview stakeholders in clinical, product, sales, and leadership, gather every asset currently making product claims, and pinpoint where the stated positioning differs from what the product and evidence genuinely support. Before we draft a single new sentence, you receive a clear view of where internal disagreement exists.
From days 30 to 60, we develop the positioning architecture and draft the core assets. We require access to clinical validation data, any available win-loss research, and time with the person responsible for the sales conversation, because positioning that has not faced a real objection is merely copywriting. We refine the language directly with those who will need to say it aloud.
Days 60 to 90 focus on rollout: refreshed website copy, sales deck, and one-pagers launch, and we brief the teams carrying the message – sales, customer success, and, where applicable, a clinical advisory function. Most initial engagements last three to four months to complete the audit, build, and rollout, with an option to continue into ongoing message testing as new buyer segments or products come online.
The cadence is one weekly working session during the build phase, shifting to biweekly during rollout, with direct access to the person leading the positioning work on our side rather than an account-manager layer. We report on adoption signals – is the language appearing correctly in sales calls and marketing assets – not vanity metrics unrelated to whether the positioning truly changed.
- Consistent core claim across clinical, sales, and marketing assets
- Shorter sales cycles at the stage where positioning gets tested by the buyer
- Clear competitive frame against the specific vendors each buyer type actually compares you to
- Positioning that clinical and regulatory stakeholders can defend, not just marketing
If your digital health company needs product positioning leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
What does a product positioning engagement cost for a digital health company?
We set a fixed project fee for positioning work based on the number of buyer segments you serve and the volume of existing assets requiring rewrites. A single-channel product targeting one buyer type has a smaller scope than a company selling concurrently to health systems, payers, and consumers.
How soon will we see results from a positioning engagement?
The architecture and revised assets are delivered within the first 90 days. Qualitative signals – prospects accurately repeating the new positioning and sales reporting fewer 'what do you actually do' questions during discovery – typically emerge within one or two months after rollout.
How will the positioning team collaborate with our clinical and regulatory staff?
During the audit phase, we interview clinical and regulatory stakeholders directly and treat their constraints as non-negotiable inputs into the final language, rather than issues to smooth over later. Every positioning claim must be one they can defend when challenged by a medical director or payer reviewer.
How is Winston Francois different from a branding or messaging agency?
A branding agency focuses on language that sounds persuasive. We focus on language that holds up through a clinical review and payer negotiation without conflicting with the sales deck.
How do you evaluate whether the new positioning is actually working?
We begin with qualitative signals – are sales, customer success, and clinical stakeholders communicating the same core claim, and are prospects accurately reflecting it back during discovery calls – because these appear before pipeline metrics change. We then monitor win rate against named competitors and time-to-close at the stage where the positioning is tested, comparing both with your pre-engagement baseline.
What kind of digital health company is best suited to this service?
This service suits companies approximately from Series A through the growth stage, in the 5M to 100M ARR range, particularly those selling to multiple buyer types – clinical, payer, employer, or consumer – whose current positioning was created for an earlier company stage or a different buyer from the one closing deals today. It is less suitable for a pre-product-market-fit company still determining what the product does well, because positioning work assumes there is a genuine, evidenced capability to position.
